MDXG Stock Risk & Deep Value Analysis
MiMedx Group Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About MDXG Stock
We analyzed MiMedx Group Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran MDXG through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
MDXG Risk Analysis & Red Flags
What Could Go Wrong
A reversal of the recent robust revenue growth or a return to unprofitability would severely impact investor confidence and valuation, especially if competitive dynamics in advanced wound care or orthopedics intensify beyond current expectations or if reimbursement changes negatively affect product adoption.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
High
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Lack of detailed insider buy/sell activity for specific executives in recent filings.
- ⚠
Absence of recent analyst consensus and price targets, indicating lower institutional visibility.
- ⚠
High competitive intensity in the broader wound care and orthopedic biologics markets.
Upcoming Risk Events
- 📅
Disappointing Q1 2026 earnings or guidance
- 📅
Increased competitive pressures or new entrant biologics
- 📅
Negative changes in reimbursement policies
When to Reconsider
- 🚪
Exit if quarterly revenue growth decelerates below 15% YoY for two consecutive quarters.
- 🚪
Sell if the company reports a GAAP net loss for two consecutive quarters.
- 🚪
Exit if key competitive product launches significantly erode market share.
Unlock MDXG Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does MiMedx Group Inc (MDXG) Do?
Market Cap
$574.95M
Sector
Healthcare
Industry
Biotechnology
Employees
837
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
Visit MiMedx Group Inc WebsiteInvestment Thesis
MiMedx Group is successfully executing a strategic turnaround, evidenced by its robust 27% YoY revenue growth and return to GAAP profitability in Q4 2025. Leveraging its proprietary biologics platform, the company is strategically expanding into higher-growth orthopedic segments while maintaining stability in wound care. This operational momentum, if sustained, positions MiMedx for significant market share gains and offers a credible, albeit high-risk, pathway to substantial value appreciation over the next 3-5 years.
Is MDXG Stock Undervalued?
Unlock the full AI analysis for MDXG
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
MDXG Price Targets & Strategy
12-Month Target
$15.00
Bull Case
$20.00
Bear Case
$5.00
Valuation Basis
30x forward P/E applied to $0.50 estimated FY26 EPS = $15.00
Entry Strategy
Dollar-cost average at current levels ($3.92) or on minor pullbacks, given strong recent earnings.
Exit Strategy
Take partial profits at $15.00, reassess at $20.00. Stop loss at $3.00 if turnaround momentum reverses.
Portfolio Allocation
5% for moderate-aggressive risk tolerance
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is MDXG Financially Healthy?
Valuation
P/E Ratio
11.84
Forward P/E
31.21
EV/EBITDA
12.18
Profitability
Gross Margin
82.56%
Operating Margin
15.26%
Net Margin
11.60%
Return on Equity
21.24%
Revenue Growth
19.99%
EPS
$0.32
Balance Sheet
Current Ratio
4.32
Quick Ratio
3.92
Debt/Equity
0.07
Cash & Equivalents
$119.00M
Cash Flow
EBITDA
$68.61M
Other
Beta (Volatility)
1.73
Does MDXG Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is durable due to the specialized nature of its biologics, the high regulatory hurdles for new regenerative medicine products, and the continuous accumulation of clinical data, which reinforces clinician trust and product adoption. Intellectual property around its processing and applications further strengthens this position.
Moat Erosion Risks
- •Development of significantly cheaper or more effective competing biologics.
- •Loss of key patent protections or regulatory exclusivity periods.
- •Intensified competition from larger, well-funded medical device or pharma companies.
MDXG Competitive Moat Analysis
Sign up to see competitive advantages
MDXG Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (No specific data provided, but strong earnings likely fostering cautious optimism)
Institutional Sentiment
Neutral (No analyst coverage or institutional activity provided)
Insider Activity (Form 4)
Changes in beneficial ownership reported via Form 4 on March 17, 2026, but specific buy/sell details by key executives or dollar values are not available in provided data.
Options Flow
Normal options activity (No specific data provided)
Earnings Intelligence
Next Earnings
Estimated early May 2026
Surprise Probability
High
Historical Earnings Pattern
Likely to react positively to strong growth and profitability; susceptible to significant downside if growth slows or profitability reverses, especially given its small-cap nature.
Key Metrics to Watch
Competitive Position
Top Competitor
ORGO (Organogenesis Holdings Inc.)
Market Share Trend
Gaining (indicated by 27% YoY revenue growth compared to competitor Orthofix's 0.4% YoY growth)
Valuation vs Peers
Cannot assess current valuation multiples vs. peers due to lack of specific MDXG valuation ratios provided.
Competitive Advantages
- •Proprietary biologics platform based on human amniotic tissue
- •Accumulated clinical evidence and established product efficacy
- •Differentiated product offerings in niche regenerative medicine
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive MDXG Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings (Estimated early May 2026)
- •Continued strong revenue growth and profitability
Medium-Term (6-18 months)
- •Expanded market penetration in orthopedic segments
- •New product launches or expanded indications for existing biologics
Long-Term (18+ months)
- •Potential market leadership in regenerative medicine niche
- •Strategic acquisition by a larger pharmaceutical or medical device company
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for MDXG?
- ✓
Sustained quarterly revenue growth above 20% YoY
- ✓
Consistent positive free cash flow generation and margin expansion
- ✓
Successful product pipeline progression and expanded market adoption
Bull Case Analysis
See what could go right with Premium
Competing with MDXG
See how MiMedx Group Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
MiMedx Group Inc MDXG | $575.0M | 7.9 | 11.8 | $393.4M | 11.6% | 20.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How MiMedx Group Inc Makes Money
MiMedx Group Inc. develops, manufactures, and markets innovative regenerative and therapeutic biologics products derived from human amniotic tissue. These products, such as EpiFix and AmnioFix, are primarily used in advanced wound care to treat chronic and acute wounds, and increasingly in surgical and orthopedic applications to aid healing and tissue regeneration. The company generates revenue by selling these proprietary biologics directly to hospitals, wound care centers, surgical facilities, and physicians through its dedicated sales force.
Read Full Business Model BreakdownFAQ
What is the DVR Score for MiMedx Group Inc (MDXG)?
As of April 14, 2026, MiMedx Group Inc has a DVR Score of 7.9 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of MiMedx Group Inc?
MiMedx Group Inc's market capitalization is approximately $575.0M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does MiMedx Group Inc use?
MDXG is the ticker symbol for MiMedx Group Inc. The company trades on the NCM.
What is the risk level for MDXG stock?
Our analysis rates MiMedx Group Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of MDXG?
MiMedx Group Inc currently has a price-to-earnings (P/E) ratio of 11.8. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is MiMedx Group Inc's revenue growing?
MiMedx Group Inc has reported revenue growth of 20.0%. The company is showing strong top-line momentum.
Is MDXG stock profitable?
MiMedx Group Inc has a profit margin of 11.6%. The company is profitable but margins are modest.
How often is the MDXG DVR analysis updated?
Our AI-powered analysis of MiMedx Group Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 14, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for MDXG (MiMedx Group Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.